



PHARMACEUTICAL 2021









PHARMACEUTICAL 2021



Avidity Biosciences Inc. Rank 61 of 409



The relative strengths and weaknesses of Avidity Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avidity Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 203% points. The greatest weakness of Avidity Biosciences Inc. is the variable Revenues, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 87%, being 441% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	331,678
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,587
Liabilities, Non-Current	13,088
Other Assets	752
Other Compr. Net Income	-5.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-78
Property and Equipment	1,468
Research and Development	37,602
Revenues	6,787
Selling, General and Administrative Expense	13,462

Output Variable	Value in 1000 USD
Assets	333,898
Liabilities	27,675
Expenses	51,064
Stockholders Equity	306,223
Net Income	-44,355
Comprehensive Net Income	-44,358
Economic Capital Ratio	87%